129 related articles for article (PubMed ID: 10492058)
1. Effect of fluvoxamine on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brøsen K
Eur J Clin Pharmacol; 1999 Aug; 55(6):451-6. PubMed ID: 10492058
[TBL] [Abstract][Full Text] [Related]
2. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brosen K
Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
[TBL] [Abstract][Full Text] [Related]
3. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
Damkier P; Brøsen K
Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
[TBL] [Abstract][Full Text] [Related]
4. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 1999 Dec; 27(12):1519-22. PubMed ID: 10627170
[No Abstract] [Full Text] [Related]
8. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Madsen H; Enggaard TP; Hansen LL; Klitgaard NA; Brøsen K
Clin Pharmacol Ther; 2001 Jan; 69(1):41-7. PubMed ID: 11180037
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and elimination of quinine in healthy volunteers.
Mirghani RA; Hellgren U; Bertilsson L; Gustafsson LL; Ericsson O
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):423-7. PubMed ID: 12920491
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin treatment greatly increases the apparent oral clearance of quinidine.
Damkier P; Hansen LL; Brøsen K
Pharmacol Toxicol; 1999 Dec; 85(6):257-62. PubMed ID: 10628900
[TBL] [Abstract][Full Text] [Related]
11. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
12. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
14. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
16. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.
Mirghani RA; Hellgren U; Westerberg PA; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1999 Nov; 66(5):454-60. PubMed ID: 10579472
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Yao C; Kunze KL; Trager WF; Kharasch ED; Levy RH
Drug Metab Dispos; 2003 May; 31(5):565-71. PubMed ID: 12695344
[TBL] [Abstract][Full Text] [Related]
19. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
Jeppesen U; Rasmussen BB; Brøsen K
Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]